Global Blood Therapeutics

layoffs

San Francisco

We finally have new drugs for sickle cell disease. Why are so few patients taking them?

Stat

Mon, 12/19/22 - 11:13 am

patients

Biopharma’s 5 Biggest M&A Deals of 2022

BioSpace

Wed, 12/14/22 - 10:50 am

Turning Point Therapeutics

Bristol Myers Squibb

ChemoCentryx

Pfizer’s dealmaking continues as GBT, Biohaven acquisitions close

Medical Marketing and Media

Wed, 10/5/22 - 10:43 am

Biohaven

No big bang for biopharma buyouts

EP Vantage

Wed, 10/5/22 - 10:29 am

Aerie Pharmaceuticals

Gilead Sciences

MiroBio

Johnson & Johnson lost to Pfizer in bidding war for Global Blood Therapeutics: Bloomberg

Fierce Pharma

Wed, 08/24/22 - 10:34 am

JNJ

Pfizer buys sickle cell drugmaker Global Blood for $5.4B

BioPharma Dive

Mon, 08/8/22 - 10:29 am

Pfizer, riding high on COVID windfall, eyes $5B play for Global Blood Therapeutics

Fierce Pharma

Sun, 08/7/22 - 11:27 pm

Why Global Blood Therapeutics Trended Upward Today

Motley Fool

Wed, 06/29/22 - 05:32 pm

clinical trials

GBT601

Ash 2021 preview – small increases and big falls

EP Vantage

Mon, 11/8/21 - 10:50 am

IGM Biosciences

Global Blood takes on gene therapy

EP Vantage

Thu, 10/28/21 - 10:36 am

Novartis, GBT sickle cell drugs face coverage hurdles as gene therapy threats loom: survey

Fierce Pharma

Wed, 06/30/21 - 12:09 am

Novartis

Adakveo

gene therapy

Fortunes diverge for solo drug launchers

EP Vantage

Tue, 05/11/21 - 11:01 am

drug launches

Intra-Cellular Therapies

Biocryst

Horizon Therapeutics

Karyopharm Therapeutics

Aurinia Pharmaceuticals

With all the buzz in gene therapy, Sanofi offloads two small molecule sickle cell programs from $11.6B buyout to Global Blood Therapeutics

Endpoints

Tue, 03/16/21 - 10:55 am

New sickle cell drugs priced too high, ICER says

BioPharma Dive

Fri, 03/13/20 - 12:43 pm

RWE

Adakveo

GBT takes a page from HIV playbook as it embarks on Oxbryta launch

Fierce Pharma

Thu, 02/13/20 - 11:31 pm

Trifecta of sickle cell disease therapies extend life expectancy, but are not cost-effective — ICER

Endpoints

Fri, 01/24/20 - 10:30 am

Emmaus Life Sciences

Endari

5 biopharmas to watch as the decade's last earnings kick off

BioPharma Dive

Wed, 01/22/20 - 11:06 am

Bluebird Bio

3 Rare Disease Drug Launches to Watch in 2020

Motley Fool

Sat, 01/4/20 - 07:38 pm

acute hepatic porphyria

FDA

5 New Drug Approvals the FDA Gave Top Priority

Motley Fool

Sat, 11/30/19 - 11:22 pm

FDA

drug approvals